CN114847490A - Tablet for improving sleep quality and preparation method thereof - Google Patents
Tablet for improving sleep quality and preparation method thereof Download PDFInfo
- Publication number
- CN114847490A CN114847490A CN202210339381.0A CN202210339381A CN114847490A CN 114847490 A CN114847490 A CN 114847490A CN 202210339381 A CN202210339381 A CN 202210339381A CN 114847490 A CN114847490 A CN 114847490A
- Authority
- CN
- China
- Prior art keywords
- tablet
- sleep quality
- improving sleep
- theanine
- improving
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003860 sleep quality Effects 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title abstract description 15
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 102
- 229940026510 theanine Drugs 0.000 claims abstract description 51
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 43
- 108010079058 casein hydrolysate Proteins 0.000 claims abstract description 41
- 239000000463 material Substances 0.000 claims abstract description 30
- 229920001202 Inulin Polymers 0.000 claims abstract description 16
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 16
- 229940029339 inulin Drugs 0.000 claims abstract description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 44
- 238000002156 mixing Methods 0.000 claims description 29
- 238000001035 drying Methods 0.000 claims description 20
- 238000010298 pulverizing process Methods 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000011248 coating agent Substances 0.000 claims description 16
- 238000000576 coating method Methods 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 13
- 235000003599 food sweetener Nutrition 0.000 claims description 12
- 235000013336 milk Nutrition 0.000 claims description 12
- 239000008267 milk Substances 0.000 claims description 12
- 210000004080 milk Anatomy 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 239000003765 sweetening agent Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 108010076119 Caseins Proteins 0.000 claims description 10
- 239000005018 casein Substances 0.000 claims description 10
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 10
- 235000021240 caseins Nutrition 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 239000000314 lubricant Substances 0.000 claims description 9
- 230000001376 precipitating effect Effects 0.000 claims description 9
- 238000007873 sieving Methods 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 230000009849 deactivation Effects 0.000 claims description 7
- 239000000945 filler Substances 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 230000001954 sterilising effect Effects 0.000 claims description 7
- 238000004659 sterilization and disinfection Methods 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 239000000845 maltitol Substances 0.000 claims description 5
- 235000010449 maltitol Nutrition 0.000 claims description 5
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 5
- 229940035436 maltitol Drugs 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 239000004386 Erythritol Substances 0.000 claims description 4
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002494 Zein Polymers 0.000 claims description 4
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 4
- 229940009714 erythritol Drugs 0.000 claims description 4
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 4
- 235000019414 erythritol Nutrition 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000005019 zein Substances 0.000 claims description 4
- 229940093612 zein Drugs 0.000 claims description 4
- 244000298479 Cichorium intybus Species 0.000 claims description 3
- 235000007542 Cichorium intybus Nutrition 0.000 claims description 3
- 244000115658 Dahlia pinnata Species 0.000 claims description 3
- 235000012040 Dahlia pinnata Nutrition 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 240000008892 Helianthus tuberosus Species 0.000 claims description 3
- 235000003230 Helianthus tuberosus Nutrition 0.000 claims description 3
- 240000007472 Leucaena leucocephala Species 0.000 claims description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 3
- -1 acetate phthalate ethanol Chemical compound 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 229910002012 Aerosil® Inorganic materials 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 abstract description 9
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 9
- 230000036506 anxiety Effects 0.000 abstract description 9
- 206010022437 insomnia Diseases 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 9
- 235000013305 food Nutrition 0.000 abstract description 8
- 208000019116 sleep disease Diseases 0.000 abstract description 8
- 230000035882 stress Effects 0.000 abstract description 8
- 230000005284 excitation Effects 0.000 abstract description 5
- 230000004630 mental health Effects 0.000 abstract description 3
- 239000003826 tablet Substances 0.000 description 46
- 230000000694 effects Effects 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 13
- 210000005036 nerve Anatomy 0.000 description 13
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 6
- 244000269722 Thea sinensis Species 0.000 description 6
- 229960001948 caffeine Drugs 0.000 description 6
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000013616 tea Nutrition 0.000 description 6
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229960003987 melatonin Drugs 0.000 description 5
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002040 relaxant effect Effects 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- 206010024642 Listless Diseases 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 208000017971 listlessness Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 229920002670 Fructan Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 206010042209 Stress Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003109 amnesic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019878 cocoa butter replacer Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000003778 fat substitute Substances 0.000 description 1
- 235000013341 fat substitute Nutrition 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 108010090785 inulinase Proteins 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 235000020334 white tea Nutrition 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The application relates to the field of health-care food, in particular to a tablet for improving sleep quality and a preparation method thereof. A tablet for improving sleep quality comprises the following components in percentage by weight: 10-65% of casein hydrolysate peptide, 1-30% of theanine, 1-5% of inulin and 21-82% of auxiliary material. It is effective in improving sleep problems such as insomnia, night wake, and difficulty in falling asleep caused by anxiety and stress, promoting deep sleep, improving sleep quality, relieving nervous excitation, improving anxiety, and promoting mental health. The application also provides a preparation method of the tablet for improving the sleep quality, and the preparation method is simple and is convenient to carry and take.
Description
Technical Field
The application relates to the field of health-care food, in particular to a tablet for improving sleep quality and a preparation method thereof.
Background
The society is rapidly developed at present, the rhythm of life of people is faster and faster, and many people have sleep problems under the influence of anxiety and stress. Data show that 27% of people worldwide have sleep problems, while 57% of the adult population have sleep problems, which seriously affect human health. The sleeping problems mainly include difficulty in falling asleep, easy awakening after falling asleep, insomnia and dreaminess, and the like. On an individual level, if the sleep is poor for a long time, it will lead to poor concentration, hypomnesis, listlessness, resistance deterioration, etc., affecting the mental state of the person, and thus affecting the working state. Inadequate sleep can also lead to the development of chronic metabolic disorders such as obesity, diabetes and hypertension.
At present, melatonin is mainly taken as a food for improving sleep in the market, which can improve sleep quality, but has no treatment effect on insomnia, and has poor effect after long-term administration, and has side effects of dizziness, headache, muscular soreness and the like. There are also fragrance candles and sleep spray products that claim to promote sleep, it is highly unknown that sleep is a state of depression and calmness of the brain and body, and that fragrance, medication, etc. odor stimuli work against it, only to make the brain more exciting.
Barbiturates, benzodiazepines, non-benzodiazepines and the like are generally used for clinically treating sleep disorder, and the medicines have quick response, definite action mechanism and good curative effect, but are easy to generate side effects such as residual effect, amnesic effect, withdrawal effect and the like after long-term administration.
Disclosure of Invention
The purpose of the application is to provide a tablet for improving sleep quality, which is beneficial to improving sleep problems such as insomnia, night awakening, difficulty in falling asleep and the like caused by anxiety and stress, promoting deep sleep, improving sleep quality, relieving nervous excitation, improving anxiety and promoting mental health.
Another object of the present application is to provide a method for preparing a tablet for improving sleep quality, which is simple and convenient to carry and take.
The technical problem to be solved by the application is solved by adopting the following technical scheme.
In one aspect, the present application provides a tablet for improving sleep quality, which includes, by weight: 10-65% of casein hydrolysate peptide, 1-30% of theanine, 1-5% of inulin and 21-82% of auxiliary material.
In another aspect, embodiments of the present application provide a method for preparing a tablet for improving sleep quality, which includes:
s1, extraction of casein hydrolysate peptides: carrying out enzymolysis, enzyme deactivation, separation, concentration, sterilization and spray drying on a milk casein aqueous solution to obtain casein hydrolysate peptide;
s2, extracting theanine: pulverizing folium Camelliae sinensis, extracting with water for several times, mixing filtrates, concentrating, precipitating with 95% ethanol, filtering, concentrating, ultrafiltering, purifying, and drying to obtain powdered theanine;
s3, pulverizing the rest materials, sieving, mixing with casein hydrolysate peptide obtained in S1 and theanine obtained in S2, granulating, drying, mixing, and tabletting.
Compared with the prior art, the embodiment of the application has at least the following advantages or beneficial effects:
the application provides a tablet for improving sleep quality, which comprises the following components in percentage by weight: 10-65% of casein hydrolysate peptide, 1-30% of theanine, 1-5% of inulin and 21-82% of auxiliary material. The casein hydrolysis peptide can effectively relieve symptoms such as insomnia, dreaminess and the like caused by stress, has the functions of relaxing people, soothing nerves and helping sleep, and the theanine has the effects of reducing blood pressure, soothing nerves, improving sleep, promoting brain functions and the like, activates inhibitory nerves of brain, calms excitatory nerves, thereby improving sleep condition and prompting people to sleep soundly. The casein hydrolysate peptide is matched with theanine, so that the sleep quality problems of insomnia, night awakening, difficulty in falling asleep and the like caused by stress, anxiety and the like can be effectively improved, and no side effect is caused.
The embodiment of the application provides a preparation method of a tablet for improving sleep quality, which comprises the following steps: extraction of casein hydrolysate peptides: mixing and hydrolyzing milk casein water solution and compound hydrolase, ultrafiltering and drying to obtain casein hydrolysate peptide; extracting theanine: pulverizing folium Camelliae sinensis, extracting with water for several times, mixing filtrates, concentrating, precipitating with 95% ethanol, filtering, concentrating, ultrafiltering, purifying, and drying to obtain powdered theanine; pulverizing the rest materials, sieving, mixing with casein hydrolysate peptide and theanine, granulating, drying, mixing, and tabletting to obtain tablet. The method has high extraction efficiency, and the obtained tablet is convenient for carrying and administration.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions of the embodiments of the present application will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
It should be noted that the embodiments and features of the embodiments in the present application may be combined with each other without conflict. The present application will be described in detail below with reference to specific examples.
In one aspect, the present application provides a tablet for improving sleep quality, comprising, in weight percent: 10-65% of casein hydrolysate peptide, 1-30% of theanine, 1-5% of inulin and 21-82% of auxiliary material.
Casein hydrolysate peptide is milk protein hydrolysate, contains bioactive decapeptide, can relieve stress symptoms, and has relaxing effect and no side effect. Decapeptides are functional small molecule peptides that resist gastrointestinal digestion, retain biological activity, and pass through small intestinal epithelial cells to a site of action. The mechanism solves the problem that the absorption of sleep-aiding components in the milk by a human body is limited, and also solves the trouble that the human body cannot drink the milk due to physical reasons such as intestines and stomach. Correctly and scientifically supplement casein hydrolysate peptide before sleep, can promote sleep and improve human health.
The casein hydrolysate peptide is also rich in various proteins in milk, can effectively whiten skin and make skin compact, tender and smooth, and is rich in L-tryptophan, so that the casein hydrolysate peptide has the effects of soothing nerves and helping sleep.
Theanine is one of the characteristic components in tea leaves, and accounts for 1-2% of the total dry matter, and is higher in some tea leaves, such as Anji white tea. Theanine is non-protein amino acid, and accounts for more than 50% of total amount of free amino acids in tea. Theanine has effects of lowering blood pressure, tranquilizing, improving sleep, promoting brain function, activating inhibitory nerve of brain, tranquilizing and exciting nerve, improving sleep condition, and promoting sleep.
It was found that the main receptor for theanine is the brain. After theanine enters the brain through brain barriers, the intragranular neurotransmitter dopamine in brain cells is obviously increased, and the dopamine is an adrenaline and noradrenaline precursor and is an important substance for conveying the excitation degree of brain nerve cells, and the release of the dopamine can greatly influence the emotion of a human. In addition, theanine may have an effect on the synthesis and breakdown of serotonin in the brain. After taking theanine, the content of tryptophan in brain is obviously increased or tends to be increased, but the content of serotonin is reduced. Theanine may reduce serotonin synthesis and increase its breakdown, or inhibit serotonin release.
Human body research shows that the intake of theanine improves the relaxed feeling of a human body through two ways, firstly, the theanine directly stimulates the formation of alpha brain waves to form deep relaxation and mental alertness, and secondly, the theanine participates in the synthesis of gamma-aminobutyric acid, thereby helping the human body to improve sleep. Compared with the other substance caffeine which can refresh and refresh the brain, the caffeine has the refreshing and exciting effects, but the caffeine which is taken alone has certain harm to human bodies, and the equal amount of caffeine exciting effects can not be generated after the tea is drunk. This is because theanine has an antagonistic effect on the excitation of caffeine production. Theanine is caffeine antagonist, and has effects of tranquilizing, reducing tension and relaxing nerve.
Inulin is a reserve polysaccharide in plants, mainly comes from the plants, is contained in protoplasts of cells in a colloidal form, is different from starch, is easily dissolved in hot water, is separated out from the water by adding ethanol, and does not react with iodine. Inulin is also very easily hydrolyzed to fructose under dilute acid, which is characteristic of all fructans. Can also be hydrolyzed into fructose by inulase. Inulin has high hygroscopicity, and free water binding ability, and can reduce water activity. This can be fully used to delay the evaporation of water in food processing, prevent the product from becoming stale, and prolong the shelf life and quality guarantee period of food. Inulin is not digested but becomes a probiotic to enter the intestine. The probiotics are helpful for culturing and increasing the number of beneficial bacteria in the digestive system, controlling weight and digestive health, and improving and controlling blood sugar.
In some embodiments of the present application, the inulin is made from one or more of Jerusalem artichoke, chicory, dahlia. The inulin content in the jerusalem artichoke is highest, the contents of the inulin in the chicory and the inulin in the dahlia are also higher, and the inulin can be quickly extracted.
In some embodiments of the present application, the adjunct includes one or more of a filler, a lubricant, and a sweetener.
The filler is an auxiliary material used for increasing the weight and the volume of the tablet and facilitating tabletting. The filler is one or more of starch, dextrin and lactose. The starch is cheap but has poor compressibility, and the dextrin is a product obtained by partial hydrolysis of the starch, and has strong adhesion, high hardness and strong adsorbability. Lactose is an excellent tablet filler, and lactose particles prepared by a spray drying method are close to spherical, have good fluidity and compressibility, and can be used for directly tabletting powder.
The lubricant can smoothly feed and discharge the tablets during tabletting, reduce sticking and reduce the friction force between granules or tablets and the wall of a die hole, and ensure that the tablets have smooth and attractive appearance. The lubricant is one or more of magnesium stearate, hydrogenated vegetable oil, and silica gel micropowder.
Magnesium stearate, an organic compound, is a white, non-gritty fine powder that has a greasy feel on contact with the skin. Insoluble in water, ethanol and diethyl ether, and can be used as lubricant, antisticking agent and glidant.
Hydrogenated vegetable oil is an artificial fat and includes well-known non-dairy creamer (creamer), margarine, cocoa butter replacer, and the like. It is made up by adding hydrogen into ordinary vegetable oil under a certain temp. and pressure and making it undergo the process of catalysis. In addition to lubricants, hydrogenated vegetable oils can be used as co-binders in tablets, as viscosity modifiers in oily liquid and semisolid formulations, to reduce sedimentation of suspended components and improve the solidification process in the preparation of suppositories, as liquid and semisolid fillings for hard gelatin capsules.
Colloidal silica, also known as colloidal silica, is very fine in particle size, difficult to measure, often expressed as specific surface area, and functions well as a glidant, typically used in an amount of about 0.1% to about 0.5%. Can be used as flow aid, catalyst carrier, etc. in the production of medicine.
The addition of a sweetening agent imparts a palatable feel to the tablet and also acts as a flavoring agent. The sweetener is one or more of sorbitol, maltitol, and erythritol.
Sorbitol, also known as sorbitol, is the major photosynthetic product of plants of the Rosaceae family. Is white hygroscopic powder or crystalline powder, tablet or granule, and has no odor. Has cool sweet taste, sweetness about half of that of cane sugar, calorific value similar to that of cane sugar, and no dental caries when used as a sweetening agent. After eating, the food is not converted into glucose in blood and is not influenced by insulin.
Maltitol is a novel sweetener, and the sweeteners eaten by people in the past are basically sugars with high heat and sweetness, and are easy to cause diseases such as diabetes, obesity, arteriosclerosis, heart failure and the like. The maltitol has high sweetness, low calorie, good safety, more sufficient raw materials, simple manufacturing process and unique performance which is not possessed by other sweeteners. The maltitol can be used in oral preparation, candy, and food, and has no caries, toxicity, allergy or irritation.
Erythritol, a bulk sweetener. Erythritol is widely present in nature, such as fungus mushroom, lichen, melon and fruit, grape, pear, eyeball crystal of animal, plasma, fetal fluid, semen, urine, and fermented food such as wine, beer, soy sauce, and Japanese sake. Has refreshing sweet taste, is not easy to absorb moisture, is stable at high temperature, is stable in a wide pH range, has mild cool feeling when dissolved in the mouth, and is suitable for various foods. It has low hygroscopicity, and can prolong the shelf life of tablet.
In some embodiments of the present application, the weight ratio of the bulking agent, the lubricant, and the sweetener is (10-20): (1-2): (20-70). Under the proportion, the tablet can be well molded, has good taste and flavor and is more palatable.
In some embodiments of the present application, the above-mentioned sleep quality improving tablet further comprises less than 1% by weight of a flavorant.
The edible spice can improve the flavor of the tablet, and is convenient for people to accept the tablet. The dosage is less, and the health is generally not harmed.
In another aspect, the present application provides a method for preparing a tablet for improving sleep quality, which comprises:
s1, extraction of casein hydrolysate peptides: carrying out enzymolysis, enzyme deactivation, separation, concentration, sterilization and spray drying on a milk casein aqueous solution to obtain casein hydrolysate peptide; the extraction method is simple and has high extraction efficiency.
S2, extracting theanine from tea leaves: pulverizing folium Camelliae sinensis, extracting with water for several times, mixing filtrates, concentrating, precipitating with 95% ethanol, filtering, concentrating, ultrafiltering, purifying, and drying to obtain powdered theanine; thus, the theanine in the tea can be effectively extracted.
S3, pulverizing the rest materials, sieving, mixing with casein hydrolysate peptide obtained in S1 and theanine obtained in S2, granulating, drying, mixing, and tabletting.
In some embodiments of the present application, at S3, after tableting, further comprising a coating material, the coating material being one or more of sucrose powder, gelatin, acacia, zein ethanol solution, and cellulose acetate phthalate ethanol solution.
The coating is that sugar or other materials capable of forming films are coated on the outer surface of the solid pharmaceutical preparation in a specific device according to a specific process, and the solid pharmaceutical preparation becomes a layer or a plurality of layers of multifunctional protective layers with different thicknesses and different elasticity and is tightly adhered to the surface after being dried. The coating can improve the appearance of the tablet, increase the stability of the drug, mask the unpleasant odor of the drug, control the site of drug release, etc. The coating material is generally sucrose powder, gelatin, acacia, zein ethanol solution, cellulose acetate phthalate ethanol solution, cellulose derivative, etc.
The features and properties of the present application are described in further detail below with reference to examples.
Examples
The raw materials were prepared according to the ingredients in table 1.
TABLE 1 compounding ratio of raw materials in examples 1 to 8 (%)
The preparation method of the tablet for improving sleep quality of example 1-2 is as follows:
extraction of casein hydrolysate peptides: carrying out enzymolysis, enzyme deactivation, separation, concentration, sterilization and spray drying on the milk casein aqueous solution to obtain the casein hydrolysate peptide.
Extracting theanine: pulverizing folium Camelliae sinensis, extracting with deionized water for several times (at 100 deg.C) at a ratio of material to liquid of 30g/ml, mixing filtrates, concentrating, precipitating with 95% ethanol, filtering, concentrating, ultrafiltering, purifying, and drying to obtain powdered theanine;
pulverizing the rest materials, sieving, mixing with casein hydrolysate peptide and theanine, granulating, drying, mixing, tabletting, and coating to obtain tablet. The coating material is sucrose powder.
The preparation method of the tablets for improving sleep quality of examples 3 to 4 is as follows:
extraction of casein hydrolysate peptides: carrying out enzymolysis, enzyme deactivation, separation, concentration, sterilization and spray drying on the milk casein aqueous solution to obtain the casein hydrolysate peptide.
Extracting theanine: pulverizing folium Camelliae sinensis, extracting with deionized water for several times (at 100 deg.C) at a ratio of material to liquid of 30g/ml, mixing filtrates, concentrating, precipitating with 90% ethanol, filtering, concentrating, ultrafiltering, purifying, and drying to obtain powdered theanine;
pulverizing the rest materials, sieving, mixing with casein hydrolysate peptide and theanine, granulating, drying, mixing, tabletting, and coating to obtain tablet. The coating material used was gelatin.
The preparation method of the tablets for improving sleep quality of examples 5 to 6 is as follows:
extraction of casein hydrolysate peptides: carrying out enzymolysis, enzyme deactivation, separation, concentration, sterilization and spray drying on the milk casein aqueous solution to obtain the casein hydrolysate peptide.
Extracting theanine: pulverizing folium Camelliae sinensis, extracting with deionized water for multiple times (at 100 deg.C) at a ratio of materials to liquid of 20g/ml, mixing filtrates, concentrating, precipitating with 95% ethanol, filtering, concentrating, ultrafiltering, purifying, and drying to obtain powdered theanine;
pulverizing the rest materials, sieving, mixing with casein hydrolysate peptide and theanine, granulating, drying, mixing, tabletting, and coating to obtain tablet. The coating material used was gum arabic.
The preparation method of the tablet for improving sleep quality of example 7 comprises the following steps:
extraction of casein hydrolysate peptides: carrying out enzymolysis, enzyme deactivation, separation, concentration, sterilization and spray drying on the milk casein aqueous solution to obtain the casein hydrolysate peptide.
Extracting theanine: pulverizing folium Camelliae sinensis, extracting with deionized water for multiple times (at 100 deg.C) at a ratio of materials to liquid of 20g/ml, mixing filtrates, concentrating, precipitating with 95% ethanol, filtering, concentrating, ultrafiltering, purifying, and drying to obtain powdered theanine;
pulverizing the rest materials, sieving, mixing with casein hydrolysate peptide and theanine, granulating, drying, mixing, tabletting, and coating to obtain tablet. The coating material used was a zein ethanol solution.
The preparation method of the tablet for improving sleep quality of example 8 is substantially the same as that of example 1-2 except that the coating material used is a cellulose acetate phthalate alcohol solution.
Examples of the experiments
To verify the effect of the tablets for improving sleep quality provided in the examples, a total of 44 patients were enrolled in the volunteer experiment. The subjects are 25-40 years old, have high work pressure, and have sleep disorder, and the Pittsburgh sleep quality index is 16-21 points. The trial is intended to preserve the personal rights of the subject as well as the safety and reliability of the test data. All subjects gave oral and written informed consent for participation.
The patients were randomly divided into three groups, and the experimental example was administered with the tablet prepared in example 2, and the comparative example was administered with melatonin. Each subject took 1 tablet (each containing 200mg of casein hydrolysate peptide) or one melatonin tablet as provided in example 2 before sleep. Subjects reacted to their sleep condition by filling out the pittsburgh sleep quality index table. Their sleep index data were collected on day 0 and day 30 of dosing, respectively, and the results are shown in tables 2 and 3.
The rating standard of Pittsburgh sleep quality index is as follows:
the quality of the sleep is good in 0-5 minutes, the quality of the sleep is still in 6-10 minutes, the quality of the sleep is general in 11-15 minutes, and the quality of the sleep is poor in 16-21 minutes.
TABLE 2 Pittsburgh sleep quality index average score
TABLE 3 score of subjects after 30 days of drug administration
The test results are shown in tables 2 and 3, and the mean score of pittsburgh sleep quality index of the subjects decreased from 16.35 to 11 on day 0 after taking the tablets provided in example 2 for 30 days, wherein the sleep quality of 22.7% of the patients was significantly improved, the sleep time was increased, the number of night awakenings was significantly reduced, and the subjects felt good mental status without significant side effects; the sleep quality index score of Pittsburgh of 72.7% of patients is reduced, but the sleep quality condition is improved and the daytime mental condition is good; the score of the pittsburgh sleep quality index of 18 percent of patients is still maintained between 16 and 21 points, and the sleep quality is not obviously improved.
In the subjects taking melatonin, 9% of the patients also had a significant improvement in sleep quality, but only 45.4% of the patients had a certain improvement in sleep quality, some of the subjects had a feeling of listlessness during the day, and 45.4% of the subjects considered to have no significant sleep-promoting effect when they were taken melatonin.
The improvement of sleep quality by taking the tablets of example 2 is better than the comparative example, and most importantly, no significant side effects are observed in the subjects of example 1.
In summary, the embodiments of the present application provide a tablet for improving sleep quality, which includes, by weight: 10-65% of casein hydrolysate peptide, 1-30% of theanine, 1-5% of inulin and 21-82% of auxiliary material. The casein hydrolysate peptide contains decapeptide, can effectively relieve symptoms of insomnia, dreaminess and the like caused by stress, has the functions of relaxing people, soothing nerves and helping sleep, and the theanine has the effects of lowering blood pressure, soothing nerves, improving sleep, promoting brain functions and the like, activates inhibitory nerves of brain, calms excitatory nerves, improves sleep condition and promotes people to sleep well. The casein hydrolysate peptide is matched with theanine, so that the sleep quality problems of insomnia, night awakening, difficulty in falling asleep and the like caused by stress, anxiety and the like can be effectively improved, and no side effect is caused. The tablet provided by the application is beneficial to improving the sleep problems such as insomnia, night awakening and difficulty in falling asleep caused by anxiety stress, promoting deep sleep, improving sleep quality, relieving nerve excitation, improving anxiety and facilitating promotion of physical and mental health.
The embodiment of the application also provides a preparation method of the tablet for improving sleep quality, which comprises the following steps: extraction of casein hydrolysate peptides: mixing and hydrolyzing milk casein water solution and compound hydrolase, ultrafiltering and drying to obtain casein hydrolysate peptide; extracting theanine: pulverizing folium Camelliae sinensis, extracting with water for several times, mixing filtrates, concentrating, precipitating with 95% ethanol, filtering, concentrating, ultrafiltering, purifying, and drying to obtain powdered theanine; pulverizing the rest materials, sieving, mixing with casein hydrolysate peptide and theanine, granulating, drying, mixing, and tabletting to obtain tablet. The method has high extraction efficiency, and the obtained tablet is convenient for carrying and administration.
The embodiments described above are some, but not all embodiments of the present application. The detailed description of the embodiments of the present application is not intended to limit the scope of the claimed application, but is merely representative of selected embodiments of the application. All other embodiments obtained by a person of ordinary skill in the art based on the embodiments in the present application without making any creative effort belong to the protection scope of the present application.
Claims (10)
1. A tablet for improving sleep quality is characterized by comprising the following components in percentage by weight: 10-65% of casein hydrolysate peptide, 1-30% of theanine, 1-5% of inulin and 21-82% of auxiliary material.
2. The tablet for improving sleep quality as claimed in claim 1, wherein the adjuvant includes one or more of a filler, a lubricant and a sweetener.
3. The tablet for improving sleep quality according to claim 2, wherein the filler is one or more of starch, dextrin and lactose.
4. The tablet for improving sleep quality according to claim 2, wherein the lubricant is one or more of magnesium stearate, hydrogenated vegetable oil, and aerosil.
5. The tablet for improving sleep quality according to claim 2, wherein the sweetener is one or more of sorbitol, maltitol, erythritol.
6. The tablet for improving sleep quality according to claim 2, wherein the weight ratio of the filler, the lubricant and the sweetener is (10-20): (1-2): (20-70).
7. The tablet for improving sleep quality according to claim 1, further comprising less than 1% by weight of a flavorant.
8. Tablet for improving sleep quality according to claim 1, characterized in that the inulin is made from one or more of Jerusalem artichoke, chicory, dahlia.
9. A method for preparing a tablet for improving sleep quality as claimed in any one of claims 1 to 8, which comprises:
s1, extraction of casein hydrolysate peptides: carrying out enzymolysis, enzyme deactivation, separation, concentration, sterilization and spray drying on a milk casein aqueous solution to obtain casein hydrolysate peptide;
s2, extracting theanine: pulverizing folium Camelliae sinensis, extracting with water for several times, mixing filtrates, concentrating, precipitating with 95% ethanol, filtering, concentrating, ultrafiltering, purifying, and drying to obtain powdered theanine;
s3, pulverizing the rest materials, sieving, mixing with casein hydrolysate peptide obtained in S1 and theanine obtained in S2, granulating, drying, mixing, and tabletting.
10. The method of claim 9, further comprising a coating after the tabletting in the step S3, wherein the coating material is one or more selected from sucrose powder, gelatin, acacia, zein ethanol solution and cellulose acetate phthalate ethanol solution.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210339381.0A CN114847490A (en) | 2022-04-01 | 2022-04-01 | Tablet for improving sleep quality and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210339381.0A CN114847490A (en) | 2022-04-01 | 2022-04-01 | Tablet for improving sleep quality and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114847490A true CN114847490A (en) | 2022-08-05 |
Family
ID=82629747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210339381.0A Pending CN114847490A (en) | 2022-04-01 | 2022-04-01 | Tablet for improving sleep quality and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114847490A (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106309605A (en) * | 2016-10-08 | 2017-01-11 | 广东太阳神集团有限公司 | Health-care food with sleeping improving function and preparation method thereof |
CN108030099A (en) * | 2017-12-29 | 2018-05-15 | 广州硕维食品技术有限公司 | It is a kind of effectively to relieve stress the prescription nutrition food and preparation method for improving sleep |
CN109771470A (en) * | 2019-03-21 | 2019-05-21 | 慕恩(广州)生物科技有限公司 | A kind of composition and preparation method thereof containing probiotics |
CN112056453A (en) * | 2020-08-31 | 2020-12-11 | 华南理工大学 | Aromatic amino acid-rich sleep improvement zymolyte and preparation method thereof |
CN113424968A (en) * | 2021-07-09 | 2021-09-24 | 北京姿美堂生物技术有限公司 | Casein zymolyte and casein zymolyte composition with sleep-aiding function and preparation method thereof |
-
2022
- 2022-04-01 CN CN202210339381.0A patent/CN114847490A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106309605A (en) * | 2016-10-08 | 2017-01-11 | 广东太阳神集团有限公司 | Health-care food with sleeping improving function and preparation method thereof |
CN108030099A (en) * | 2017-12-29 | 2018-05-15 | 广州硕维食品技术有限公司 | It is a kind of effectively to relieve stress the prescription nutrition food and preparation method for improving sleep |
CN109771470A (en) * | 2019-03-21 | 2019-05-21 | 慕恩(广州)生物科技有限公司 | A kind of composition and preparation method thereof containing probiotics |
CN112056453A (en) * | 2020-08-31 | 2020-12-11 | 华南理工大学 | Aromatic amino acid-rich sleep improvement zymolyte and preparation method thereof |
CN113424968A (en) * | 2021-07-09 | 2021-09-24 | 北京姿美堂生物技术有限公司 | Casein zymolyte and casein zymolyte composition with sleep-aiding function and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
李靓;林智;何普明;韩铨;阮征;吕海鹏;谭俊峰;郭丽;: "茶氨酸改善小鼠睡眠状况的实验研究", 食品科学, no. 15 * |
糜漫天: "《营养生物技术与转化应用》", 30 September 2020, 中国轻工业出版社, pages: 294 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4951162B2 (en) | Sleep improvement composition | |
JP6271472B2 (en) | A deep sleep disorder improving agent containing glycine | |
RU2573990C2 (en) | Preparation, containing amino acids and plants, and its activity in alcohol detoxication | |
CN1433304A (en) | Compositions for promoting sleep | |
JP2014015480A (en) | Use of saffron and/or safranal and/or picrocrocin and/or crocin and/or derivatives thereof for treatment of obesity | |
JP2007031371A (en) | Ameliorant for sleep disturbance | |
EP1328280B1 (en) | Composition for the treatment of dysglucaemia and method for the production of said composition | |
CN111802644A (en) | Food composition for improving sleep | |
WO2007042745A1 (en) | Chocolate based appetite suppressant | |
CN114847490A (en) | Tablet for improving sleep quality and preparation method thereof | |
JPH1025246A (en) | Oral hypnotic agent, hypnotic beverage and food, and hypnotic feed | |
CN111700950B (en) | Natural-source anti-anxiety sleep-aiding sublingual tablet | |
JP3240345B2 (en) | Oral hypnotics, hypnotic foods and drinks | |
KR102245027B1 (en) | Composition for improving sleep disorder containing lettuce and Scutellariae extract as an active ingredient | |
CN114081175A (en) | Composition and application thereof in preparation of sleep improvement product | |
JP2005289948A (en) | Sleep improvement composition | |
JP2006333872A (en) | Food containing glycine and use thereof | |
TWI803146B (en) | Use of longan flower extract for increasing melatonin in individuals | |
JP2019142852A (en) | New composition | |
WO2024034424A1 (en) | Composition for enhancing motivation | |
KR102202224B1 (en) | A composition for the prevention or treatment of depression comprising herb extract YJ06 | |
CN112584711A (en) | Deep body temperature lowering agent, food, and sleep improving agent | |
CN112056535A (en) | Lung nourishing soup | |
CN114403278A (en) | Hawthorn fruit-flavored alcohol-dispelling tabletting candy and preparation method thereof | |
CN114158642A (en) | Nutritional type tablet candy and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |